Palatin Technologies provided a corporate update, highlighted the company’s key calendar year 2023 accomplishments and outlined its anticipated calendar year 2024 clinical development milestones. “We made significant operational progress during calendar year 2023 and we believe we are well-positioned for making calendar year 2024 a pivotal and transformative year for Palatin,” said Carl Spana, Ph.D., President and CEO of Palatin. “Our internal research and development efforts are focused in areas where we believe we have a high probability of success, product differentiation and the opportunity for a substantial return on our investment. Topline data readout for our Phase 3 PL9643 clinical study for DED is expected early in the first quarter of calendar year 2024. Our Phase 2 study of oral PL8177 in patients with UC is expected to have an interim analysis data readout in the first quarter and topline trial results in the second quarter of calendar year 2024.” Dr. Spana further commented, “We are excited by the significant opportunity of melanocortin-based therapeutics for obesity treatment and believe we are well positioned to deliver selective and efficacious MCR4 long-acting peptides and orally active small molecules. We expect to commence a Phase 2 clinical study of a MCR4 agonist plus a GLP-1 in obese patients in the first quarter of calendar year 2024. In addition, following on our significant expertise in product development to treat sexual dysfunction, we expect to commence a Phase 2 clinical study evaluating bremelanotide co-formulated with a PDE5i for the treatment of ED in patients that do not respond to PDE5i monotherapy in the first quarter of calendar year 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PTN:
- Biotech Alert: Searches spiking for these stocks today
- Palatin completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171M
- Palatin: NYSE American accepts listing standards compliance plan
- Palatin files to sell 2.48M shares of common stock for holders
- Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update